The migraine treatment drug candidate, MSRX-202, leverages MonoSol PharmFilm technology in a combination product that includes rizatriptan for the treatment of migraine pain and ondansetron for the treatment of nausea.
MonoSol Rx president and chief executive officer Mark Schobel said that MSRX-202 represents a new approach to migraine treatment that addresses both pain and nausea.
"MSRX-202 fulfills this unmet patient need and additionally has the potential to be the fastest acting oral migraine pain medication on the market," Schobel added.
"Our preclinical and first-in-man pharmacokinetic studies indicate that the therapeutic dose will provide relief from pain in as little as fifteen minutes without the use of a device."
Preclinical and first-in-human pharmacokinetic studies indicate that MSRX-202 will reach therapeutic levels for rizatriptan in as little as fifteen minutes while maintaining the well-known pharmacokinetic profile of ondansetron, according to the company.